СIRCULATING MIRNAS AS PREDICTIVE MARKERS FOR LINE I AND II NEOADJUVANT CHEMOTHERAPY IN TRIPLE-NEGATIVE BREAST CANCER
DOI:
https://doi.org/10.15407/exp-oncology.2025.01.016Keywords:
miRNA, triple-negative breast cancer, drug resistanceAbstract
Background. miRNAs have emerged as promising biomarkers for breast cancer, particularly in predicting treatment response and prognosis. Their ability to regulate gene expression and their presence in various bodily fluids make them valuable tools for personalized medicine. Materials and Methods. The study was based on a retrospective analysis of the results of the examination, treatment, and survival of 94 patients with stage II—III triple-negative breast cancer (TNBC) who underwent treatment at the Kyiv City Clinical Oncology Center during 2013—2017. miRNA expressions in blood serum were estimated using the real-time RT-PCR. Results. The elevated levels of miR-21, -155, -199a, and -200b (p < 0.05) were linked to metastasis to regional lymph nodes, while miR-373 and -126 expression levels were associated with the tumor stage (r = 0.55 and 0.57, respectively, p < 0.05). The higher serum levels of miR-21 (> 5.4, p < 0.05), -125b (> 6.0, p < 0.05) and the lower miR-205 levels (< 2.0, p < 0.05) were associated with the poorer response to line I and II neoadjuvant chemotherapy. The serum levels of miR-21, -125b, -126, -199a, -200b, -205, and -373 were found to correlate with the overall and recurrence-free survivals in TNBC patients. Conclusions. These findings suggest that miRNA-based biomarkers may have the potential as prognostic and predictive tools in TNBC, aiding in personalized treatment strategies.
References
Bhushan A, Gonsalves A, Menon JU. Current state of breast cancer diagnosis, treatment, and theranostics. Pharma- ceutics. 2021;13(5):723. https://doi.org/10.3390/pharmaceutics13050723
Tarighati E, Keivan H, Mahani H. A review of prognostic and predictive biomarkers in breast cancer. Clin Exp Med.
;23(1):1-16. https://doi.org/10.1007/s10238-021-00781-1
Fuksa L, Micuda S, Grim J, et al. Predictive biomarkers in breast cancer: their value in neoadjuvant chemotherapy.
Cancer Invest. 2012;30(9):663-678. https://doi.org/10.3109/07357907.2012.725441
Asaoka M, Gandhi S, Ishikawa T, Takabe K. Neoadjuvant chemotherapy for breast cancer: past, present, and future.
Breast Cancer (Auckl). 2020;14:1178223420980377. https://doi.org/10.1177/1178223420980377
Bou Zerdan M, Ghorayeb T, Saliba F, et al. Triple negative breast cancer: Updates on classification and treatment in 2021. Cancers (Basel). 2022;14(5):1253. https://doi.org/10.3390/cancers14051253
Sabit H, Cevik E, Tombuloglu H, et al. Triple negative breast cancer in the era of miRNA. Crit Rev Oncol Hematol. 2021;157:103196. https://doi.org/10.1016/j.critrevonc.2020.103196
Sueta A, Fujiki Y, Goto-Yamaguchi L, et al. Exosomal miRNA profiles of triple-negative breast cancer in neoadju- vant treatment. Oncol Lett. 2021;22(6):819. https://doi.org/10.3892/ol.2021.13080
Motamedi M, Hashemzadeh Chaleshtori M, Ghasemi S, Mokarian F. Plasma level of miR-21 and miR-451 in prima- ry and recurrent breast cancer patients. Breast Cancer (Dove Med Press). 2019;11:293-301. https://doi.org/10.2147/ BCTT.S224333
Piasecka D, Braun M, Kordek R, Sadej R, Romanska H. MicroRNAs in regulation of triple-negative breast cancer progression. J Cancer Res Clin Oncol. 2018;144(8):1401-1411. https://doi.org/10.1007/s00432-018-2689-2
Zhang C, Sun C, Zhao Y, et al. Overview of microRNA as diagnostic and prognostic biomarkers for high-incidence cancers in 2021. Int J Mol Sci. 2022;23(19):11389. https://doi.org/10.3390/ijms231911389
Zhao R, Wu J, Jia W, et al. Plasma miR-221 as a predictive biomarker for chemoresistance in breast cancer patients who previously received neoadjuvant chemotherapy. Onkologie. 2011;34(12):675-680. https://doi.org/10.1159/000334552
Wang XX, Ye FG, Zhang J, et al. Serum miR-4530 sensitizes breast cancer to neoadjuvant chemotherapy by sup- pressing RUNX2. Cancer Manag Res. 2018;10:4393-4400. https://doi.org/10.2147/CMAR.S172205
Qattan A, Al-Tweigeri T, Alkhayal W, et al. Clinical identification of dysregulated circulating micrornas and their implication in drug response in triple negative breast cancer (TNBC) by Target Gene Network and Meta-Analysis. Genes (Basel). 2021;12(4):549. https://doi.org/10.3390/genes12040549
García-Vazquez R, Ruiz-García E, Meneses García A, et al. A microRNA signature associated with patho- logical complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer. Tumour Biol. 201;39(6):1010428317702899. https://doi.org/10.1177/1010428317702899
Chekhun V, Mushii O, Zadvornyi T, et al. Features of COL1A1 expression in breast cancer tissue of young patients.
Exp Oncol. 2023;45(3):351-363. https://doi.org/10.15407/exp-oncology.2023.03.351
Santana T, de Oliveira Passamai L, de Miranda FS, et al. The role of miRNAs in the prognosis of triple-negative breast cancer: a systematic review and meta-analysis. Diagnostics (Basel). 2022;13(1):127. https://doi.org/10.3390/ diagnostics13010127
Pucci P, Rescigno P, Sumanasuriya S, et al. Hypoxia and noncoding RNAs in taxane resistance. Trends Pharmacol Sci. 2018;39(8):695-709. https://doi.org/10.1016/j.tips.2018.05.002
Shao B, Wang X, Zhang L, et al. Plasma microRNAs predict chemoresistance in patients with metastatic breast can- cer. Technol Cancer Res Treat. 2019;18:1533033819828709. https://doi.org/10.1177/1533033819828709
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
